Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies-Reference-Cited by-同舟云学术

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies

Published:2018-10-01 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Madelain Vincent^ORCID,Baize Sylvain,Jacquot Frédéric,Reynard Stéphanie^ORCID,Fizet Alexandra,Barron Stephane,Solas Caroline,Lacarelle Bruno,Carbonnelle Caroline,Mentré France,Raoul Hervé^ORCID,de Lamballerie Xavier^ORCID,Guedj Jérémie^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-06215-z.pdf

Reference64 articles.

1. World Health Organization. Ebola Virus Disease: Situation Report (WHO, 2016).

2. Sissoko, D. et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 13, e1001967 (2016).

3. Dunning, J. et al. Experimental treatment of Ebola virus disease with brincidofovir. PLoS ONE 11, e0162199 (2016).

4. PREVAIL, I. & Team, M.-N. P. I. S. A randomized, controlled trial of ZMapp for ebola virus infection. N. Engl. J. Med. 375, 1448 (2016).

5. Dunning, J. et al. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med. 13, e1001997 (2016).

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease;Viruses;2024-07-09

2. Immunogenetic Profile Associated with Patients Living with HIV-1 and Epstein–Barr Virus (EBV) in the Brazilian Amazon Region;Viruses;2024-06-24

3. Development of a SARS‐CoV‐2 viral dynamic model for patients with COVID‐19 based on the amount of viral RNA and viral titer;CPT: Pharmacometrics & Systems Pharmacology;2024-05-23

4. A Critical Assessment of Remdesivir;Current Drug Therapy;2023-10-31

5. SARS‐CoV‐2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy;CPT: Pharmacometrics & Systems Pharmacology;2023-08-21